Patents Assigned to Kenji Kangawa
-
Patent number: 9573986Abstract: The present invention provides a peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 22, 2010Date of Patent: February 21, 2017Assignee: KENJI KANGAWAInventors: Kenji Kangawa, Masayasu Kojima, Hiroshi Hosoda, Hisayuki Matsuo, Yoshiharu Minamitake
-
Publication number: 20120264691Abstract: It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to 7 is a buffer solution, especially, glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer, and the concentration of the ghrelins in the solution is from 0.03 nmol/mL to 6 ?mol/mL.Type: ApplicationFiled: March 6, 2012Publication date: October 18, 2012Applicants: Kenji Kangawa, Daiichi Sankyo Company, LimitedInventors: Yoshiharu MINAMITAKE, Masaru Matsumoto
-
Publication number: 20110077195Abstract: An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.Type: ApplicationFiled: August 2, 2010Publication date: March 31, 2011Applicants: ASUBIO PHARMA CO., LTD., KENJI KANGAWAInventors: Masaru Matsumoto, Masako Matsumoto, Takeshi Hanada, Naomi Wakabayashi
-
Publication number: 20080193997Abstract: An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.Type: ApplicationFiled: August 24, 2005Publication date: August 14, 2008Applicants: Kenji Kangawa, Asubio Pharma Co., Ltd.Inventors: Masaru Matsumoto, Masako Matsumoto, Takeshi Hanada, Naomi Wakabayashi
-
Publication number: 20060166871Abstract: It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to 7 is a buffer solution, especially, glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer, and the concentration of the ghrelins in the solution is from 0.03 nmol/mL to 61 ?mol/mL.Type: ApplicationFiled: May 21, 2003Publication date: July 27, 2006Applicants: DAIICHI SUNTORY PHARMA., LTD., KENJI KANGAWAInventors: Yoshiharu Minamitake, Masaru Matsumoto
-
Patent number: 5910416Abstract: Adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomdullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.Type: GrantFiled: January 7, 1998Date of Patent: June 8, 1999Assignees: Shionogi & Co., Ltd., Kenji KangawaInventors: Kazuo Kitamura, Kenji Kangawa, Hisayuki Matsuo, Tanenao Eto
-
Patent number: 5837823Abstract: According to the present invention, adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomdullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.Type: GrantFiled: June 7, 1995Date of Patent: November 17, 1998Assignees: Shinonogi & Co., Ltd., Kenji KangawaInventors: Kazuo Kitamura, Kenji Kangawa, Hisayuki Matsuo, Tanenao Eto
-
Patent number: 5830703Abstract: According to the present invention, adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomdullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.Type: GrantFiled: February 18, 1997Date of Patent: November 3, 1998Assignees: Shionogi & Co., Ltd., Kenji KangawaInventors: Kazuo Kitamura, Kenji Kangawa, Hisayuki Matsuo, Tanenao Eto
-
Patent number: 5639855Abstract: According to the present invention, adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomedullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.Type: GrantFiled: April 26, 1994Date of Patent: June 17, 1997Assignees: Shionogi & Co., Ltd., Kenji KangawaInventors: Kazuo Kitamura, Kenji Kangawa, Hisayuki Matsuo, Tanenao Eto